Over the latest trailing 12-month period, total return cagr is -4.12%. The comparable SPY value is +16.94%. Year-to-date total return is +2.73%. Total return includes price appreciation and reinvested dividends.
Over the past 12 months, Total Return CAGR is -4.12%. Total return includes dividends reinvested. The total return CAGR includes both price appreciation and dividends reinvested. This gives a more complete picture of the company's investment performance.
Bicara Therapeutics Inc. Common Stock (BCAX)
Total Return growth vs the same calendar quarter one year earlier, last 6 comparable quarters.
Quarter-end value of $100 invested at the start of the available history, with dividends reinvested; the newest quarter may be quarter-to-date. Q4 2026 (2026-10-05): $73.86.
| Year | Total return for the year |
|---|---|
| 2026 (YTD) | +2.73% |
| 2025 | -3.39% |
| Period | Period End | QoQ Return | YoY Return |
|---|---|---|---|
| Q4 2026 (QTD) | 2026-10-05 | -7.1% | +2.7% |
| Q3 2026 | 2026-09-30 | -37.3% | +17.9% |
| Q2 2026 | 2026-06-30 | +49.3% | +219.6% |
| Q1 2026 | 2026-03-31 | +18.2% | +52.6% |
| Q4 2025 | 2025-12-31 | +6.6% | -3.4% |
| Q3 2025 | 2025-09-30 | +70.0% | -38.0% |
| Q2 2025 | 2025-06-30 | -28.7% | N/A |
| Q1 2025 | 2025-03-31 |
| -25.2% |
| N/A |
| Q4 2024 | 2024-12-31 | -31.6% | N/A |
| Q3 2024 | 2024-09-30 | N/A | N/A |
Calendar returns: QoQ compares the prior calendar quarter; YoY compares the same calendar quarter a year earlier. The newest quarter is in progress (quarter-to-date).
